Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Tucatinib with Trastuzumab Emtansine for her2-Positive Metastatic Breast Cancer
In the HER2CLIMB-02 trial, the addition of tucatinib to T-DM1 improved progression-free survival among patients with HER2-positive breast cancer, showing an increase from 7.4 to 9.
New Protocol: Periop Tislelizumab with Chemotherapy for Resectable NSCLC
The RATIONALE-315 trial demonstrated that peri-operative tislelizumab with chemotherapy significantly improved overall survival and event-free survival compared to chemotherapy alo
New Drug: Sacituzumab Tirumotecan for Advanced Urothelial Carcinoma
Sacituzumab Tirumotecan demonstrated promising antitumor activity in advanced urothelial carcinoma with an ORR of 31% and a mOS of 12.1 months. Safety profile was manageable with n
New Protocol: Preoperative PAXG for Pancreatic Cancer
Preoperative PAXG significantly improved event-free survival compared to mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma. PAXG demonstrated a fa
New Reference: Nivolumab with Ipilimumab for Non-Colorectal MSI-H/dMMR Tumors
The MOST-CIRCUIT trial showed that combined treatment with nivolumab and ipilimumab achieved a high objective response rate and prolonged progression-free survival in patients with
New Protocol: Mosunetuzumab subQ with Polatuzumab Vedotin for Rel/Reg Large B-Cell Lymphoma
The SUNMO trial demonstrated that the combination of mosunetuzumab and polatuzumab vedotin improved overall response rate and progression-free survival compared to R-GemOx in trans
New Protocol: Fuzuloparib with Apatinib for BRCA1/2 Mutated Breast Cancer
The interim analysis of the FABULOUS study showed that fuzuloparib combined with apatinib significantly improved progression-free survival compared with chemotherapy in patients wi
New Reference: Adjuvant Capecitabine for Triple-Negative Breast Cancer
The SYSUCC-001 trial showed that metronomic capecitabine as extended adjuvant therapy significantly improves 10-year disease-free survival in early triple-negative breast cancer. A
New Reference: Amivantamab – Lazertinib for NSCLC with Atypical EGFR Mutations
In the CHRYSALIS-2 study, amivantamab plus lazertinib showed a 52% overall response rate in patients with atypical EGFR-mutated advanced NSCLC. The combination treatment led to a m
